Skip to main content

Table 3 Baseline characteristics at start of teriflunomide 14 mg (core and extension period; safety population)

From: Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis

  Treatment naive (n = 1018) Previously treated with another DMT (n = 163) Recently treated with another DMT (n = 158) Overall Population (N = 1696)a
Age, mean (SD) years 38.64 (9.06) 37.82 (8.24) 38.97 (9.62) 38.68 (9.12)
Female gender, n (%) 718 (70.5) 125 (76.7) 114 (72.2) 1211 (71.4)
White, n (%) 918 (90.3)b 154 (95.1)c 154 (97.5) 1536 (90.7)d
Time since diagnosis of MS, mean (SD) years 5.06 (5.44)b 7.95 (5.38) 6.18 (6.04) 5.80 (5.60)e
Time since first symptoms of MS, mean (SD) years 8.20 (6.71)b 10.72 (6.69) 9.39 (7.19) 8.90 (6.87)e
Number of relapses within past year, mean (SD) 1.00 (0.82)f 1.22 (0.85)g 0.90 (0.88)h 0.87 (0.84)i
Baseline EDSS score
 Mean (SD) 2.59 (1.43) 2.74 (1.40) 2.49 (1.38) 2.58 (1.43)
 Median (min, max) 2.50 (0.0, 8.0) 2.50 (0.0, 6.5) 2.00 (0.0, 6.5) 2.50 (0.0, 8.0)
Last prior DMT,j,k n (%)
 Fingolimod 2 (1.8) 3 (1.8) 0 5 (0.6)
 GA 36 (33.0) 58 (35.6) 27 (17.1) 121 (15.4)
 IFNBl 1 (0.9) 0 2 (1.3) 3 (0.4)
 IFNB-1a 39 (35.8) 68 (41.7) 110 (69.6) 217 (27.6)
 IFNB-1b 31 (28.4) 31 (19.0) 19 (12.0) 81 (10.3)
 Natalizumab 0 3 (1.8) 0 3 (0.4)
 Teriflunomide 7 mg 0 0 0 357 (45.4)
  1. aIncludes an additional cohort of 357 patients from the TOWER and TENERE studies who switched from teriflunomide 7 mg to 14 mg in the extension period; bn = 1017; cn = 162; dn = 1694; en = 1695; fn = 958; gn = 143; hn = 151; in = 1609; jData reported in the treatment-naive subgroup include patients with DMT use > 2 years prior to receiving teriflunomide 14 mg (n = 109); kLast prior DMT data were based on a total of 787 patients for the overall population; lIFNB formulation not specified; DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, GA glatiramer acetate, IFNB interferon beta, max maximum, min minimum, MS multiple sclerosis, SD standard deviation
\